RU2001106614A - Растворимые в воде пролекарства из затрудненных спиртов или фенолов - Google Patents
Растворимые в воде пролекарства из затрудненных спиртов или феноловInfo
- Publication number
- RU2001106614A RU2001106614A RU2001106614/04A RU2001106614A RU2001106614A RU 2001106614 A RU2001106614 A RU 2001106614A RU 2001106614/04 A RU2001106614/04 A RU 2001106614/04A RU 2001106614 A RU2001106614 A RU 2001106614A RU 2001106614 A RU2001106614 A RU 2001106614A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- taxol
- formula
- exception
- Prior art date
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims 7
- 150000001298 alcohols Chemical class 0.000 title 1
- 150000002989 phenols Chemical class 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940002612 prodrugs Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 30
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 229960001592 Paclitaxel Drugs 0.000 claims 5
- 229930003347 taxol Natural products 0.000 claims 5
- 229910001413 alkali metal ion Inorganic materials 0.000 claims 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N Propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)aniline Chemical group CCOP(=O)(OCC)CC1=CC=C(N)C=C1 ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- KADXVMRYQRCLAH-UHFFFAOYSA-N N'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 229940035504 Tromethamine Drugs 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000003444 anaesthetic Effects 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 235000009808 lpulo Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229960004134 propofol Drugs 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- 0 CC(C)c(cccc1C(C)C)c1OCOP(**)(O*)=O Chemical compound CC(C)c(cccc1C(C)C)c1OCOP(**)(O*)=O 0.000 description 1
- RLRYVSPPZJKEPF-UHFFFAOYSA-N CC(C)c1cccc(C(C)C)c1OCOCC(C)(C=O)O Chemical compound CC(C)c1cccc(C(C)C)c1OCOCC(C)(C=O)O RLRYVSPPZJKEPF-UHFFFAOYSA-N 0.000 description 1
Claims (21)
1. Соединение формулы I
где R-O- представляет собой остаток фармацевтического соединения, содержащего спирт или фенол, за исключением таксола и производных таксола,
R1 является водородом или ионом щелочного металла или протонированным амином или протонированной аминокислотой,
R2 является водородом или ионом щелочного металла или протонированным амином или протонированной аминокислотой,
n является целым числом 1 или 2;
m является целым числом и имеет значение по крайней мере 1;
и его фармацевтически приемлемые соли.
2. Соединение по п.1, отличающееся тем, что указанное содержащее спирт или содержащее фенол соединение выбирают из группы, состоящей из камптотецина, аналогов камптотецина, пропофола, этопозида, витамина Е и циклоспорина А.
3. Соединение по п.1, отличающееся тем, что ион щелочного металла для R и R2 каждый независимо выбирают из группы, включающей натрий, калий и литий.
5. Соединение по п.4, отличающееся тем, что Z независимо выбирают из группы, состоящей из натрия, трометамина, триэтаноламина, триэтиламина, аргинина, лизина, этаноламина и N-метилглюкамина.
10. Соединение по п.8, отличающееся тем, указанную фосфоно-защитную группу выбирают из группы, включающей бензильную группу, трет-бутильную группу и аллильную группу, а также другие приемлемые защитные группы для фосфоновой группы.
11. Фармацевтическая композиция, содержащая эффективное количество соединения по п.1 и фармацевтически приемлемый носитель.
13. Способ получения соединения по п.6, включающий взаимодействие соединения формулы R-O-H, где R-O- R-O- представляет собой остаток фармацевтического соединения, содержащего спирт или фенол, за исключением таксола и производных таксола, и их фармацевтически приемлемых солей с диметилсульфоксидом в присутствии уксусного ангидрида и уксусной кислоты, и выделение продукта.
14. Способ получения соединения п.8, включающий взаимодействие соединения формулы IV
где R-O- представляет собой остаток фармацевтического соединения, содержащего спирт или фенол, за исключением таксола и производных таксола, и их фармацевтически приемлемых солей, с N-иодсукцинамидом и защищенной фосфорной кислотой формулы НОР(О) (OY)2, где Y представляет собой фосфонозащитную группу; и выделение продукта.
15. Способ по п.14, отличающийся тем, что фосфонозащитную группу выбирают из группы, включающей бензильную группу, трет-бутильную группу и аллильную группы.
16. Способ лечения, включающий введение пациенту, нуждающемуся в лечении, эффективного количества композиции по п.11.
17. Способ по п.16, отличающийся тем, что указанное соединение вводят перорально.
18. Способ по п.16, отличающийся тем, что указанное соединение вводят парентерально.
19. Применение соединения формулы 1 в качества лекарственного средства.
20. Применение по п.19, отличающееся тем, что указанное соединение представляет собой производное пропофола и лекарственное средство оказывает анестезирующий эффект.
21. Применение по п.19, отличающееся тем, что указанное соединение, за исключением производных пропофола, и лекарственное средство обладает противоопухолевой активностью.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/131,385 | 1998-08-07 | ||
US09/131,385 US6204257B1 (en) | 1998-08-07 | 1998-08-07 | Water soluble prodrugs of hindered alcohols |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001106614A true RU2001106614A (ru) | 2003-07-10 |
RU2235727C2 RU2235727C2 (ru) | 2004-09-10 |
Family
ID=22449234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001106614/04A RU2235727C2 (ru) | 1998-08-07 | 1999-08-06 | Растворимые в воде фосфонооксиметиловые эфиры затрудненных спиртов или фенолов, фармацевтические композиции на их основе, способ анестезии и способ лечения опухолевых заболеваний |
Country Status (27)
Country | Link |
---|---|
US (4) | US6204257B1 (ru) |
EP (2) | EP1102776B1 (ru) |
JP (1) | JP4554081B2 (ru) |
KR (1) | KR100662799B1 (ru) |
CN (2) | CN1680402A (ru) |
AT (1) | ATE319723T1 (ru) |
AU (1) | AU769755B2 (ru) |
BR (1) | BR9912853A (ru) |
CA (1) | CA2339834C (ru) |
CY (1) | CY1105043T1 (ru) |
CZ (1) | CZ304020B6 (ru) |
DE (1) | DE69930269T2 (ru) |
DK (1) | DK1102776T3 (ru) |
ES (1) | ES2268876T3 (ru) |
HK (1) | HK1047939B (ru) |
HU (1) | HU229401B1 (ru) |
IL (1) | IL141316A (ru) |
MX (1) | MXPA01001431A (ru) |
NO (1) | NO330357B1 (ru) |
NZ (1) | NZ509795A (ru) |
PL (1) | PL198141B1 (ru) |
PT (1) | PT1102776E (ru) |
RU (1) | RU2235727C2 (ru) |
TR (1) | TR200100772T2 (ru) |
UA (1) | UA73479C2 (ru) |
WO (1) | WO2000008033A1 (ru) |
ZA (1) | ZA200101039B (ru) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US7097849B2 (en) * | 1998-08-19 | 2006-08-29 | Jagotec Ag | Injectable aqueous dispersions of propofol |
US6362172B2 (en) * | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
US6362234B1 (en) * | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
RU2290196C2 (ru) * | 2001-04-20 | 2006-12-27 | Дебиофарм С.А. | Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение |
WO2003026632A2 (en) * | 2001-09-26 | 2003-04-03 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
US7229978B2 (en) * | 2001-12-21 | 2007-06-12 | Mgi Gp, Inc. | Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol |
KR20040080444A (ko) * | 2001-12-28 | 2004-09-18 | 길포드 파마슈티컬스 인코포레이티드 | 수용성인 프로포폴 전구약물의 약학적 수성 제제 |
NZ535484A (en) * | 2002-04-08 | 2009-01-31 | Mgi Gp Inc | Pharmaceutical compositions containing fospropofol (O-phosphonooxymethylpropofol) and methods of administering same |
ITRM20020306A1 (it) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | Esteri in posizione 20 di camptotecine. |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
ZA200504940B (en) * | 2003-01-28 | 2006-09-27 | Xenoport Inc | Amino acid derived prodrugs of propofol, compositions and uses thereof |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
US7230003B2 (en) * | 2003-09-09 | 2007-06-12 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
CA2543166A1 (en) * | 2003-10-24 | 2005-05-19 | Auspex Pharmaceuticals, Inc. | Ph sensitive prodrugs of 2,6-diisopropylphenol |
US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
WO2005058250A2 (en) * | 2003-12-17 | 2005-06-30 | Mgi Gp, Inc. | Methods of administering water-soluble prodrugs of propofol for extended sedation |
SG185306A1 (en) | 2004-04-15 | 2012-11-29 | Onyx Therapeutics Inc | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US20050256324A1 (en) * | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
US8088741B2 (en) * | 2004-05-10 | 2012-01-03 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
WO2006014282A2 (en) * | 2004-07-06 | 2006-02-09 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
WO2006017352A1 (en) * | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
US7241807B2 (en) * | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
KR20070053214A (ko) * | 2004-08-26 | 2007-05-23 | 니콜라스 피라말 인디아 리미티드 | 신규 생분해성 링커를 함유하는 프로드럭 |
EP1791521A4 (en) * | 2004-09-17 | 2009-10-21 | Eisai Corp North America | METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE |
CA2586410A1 (en) * | 2004-12-23 | 2006-07-06 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
CA2611831C (en) | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
CN101247809A (zh) * | 2005-07-12 | 2008-08-20 | Mgigp公司 | 用于诱导轻度至中度镇静水平的丙泊酚前药定量给药方法 |
ES2441608T3 (es) | 2005-08-18 | 2014-02-05 | Zimmer Gmbh | Artículos de polietileno de peso molecular ultra-alto y métodos para formar artículos de polietileno de peso molecular ulra-alto |
US20080234229A1 (en) * | 2005-08-18 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
WO2007028104A2 (en) * | 2005-09-02 | 2007-03-08 | Auspex Pharmaceuticals, Inc. | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
US20090114877A1 (en) * | 2005-09-13 | 2009-05-07 | Eisai R&D Management Co., Ltd. | Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same |
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
DK2041158T3 (da) * | 2006-06-19 | 2013-06-24 | Onyx Therapeutics Inc | Peptid-epoxidketoner til proteasom inhibering |
JP2010505826A (ja) * | 2006-10-05 | 2010-02-25 | エーザイ インコーポレイテッド | プロポフォールの水溶性プロドラッグの水ベースの薬学的製剤 |
WO2008052044A2 (en) * | 2006-10-26 | 2008-05-02 | Xenoport, Inc. | Use of derivatives of propofol for treating diseases associated with oxidative stress |
EP2578248B1 (en) | 2007-04-10 | 2021-05-19 | Zimmer, Inc. | An antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications |
US8664290B2 (en) | 2007-04-10 | 2014-03-04 | Zimmer, Inc. | Antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications |
AU2008251484A1 (en) | 2007-05-09 | 2008-11-20 | Pharmacofore, Inc. | Therapeutic compounds |
CA2685570A1 (en) | 2007-05-09 | 2008-11-20 | Pharmacofore, Inc. | Therapeutic compounds |
WO2008157627A1 (en) * | 2007-06-21 | 2008-12-24 | Xenoport, Inc. | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus |
FI20070574A0 (fi) * | 2007-07-30 | 2007-07-30 | Kuopion Yliopisto | Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke |
EP2188870A1 (en) * | 2007-09-13 | 2010-05-26 | Aerosat Corporation | Communication system with broadband antenna |
US8427384B2 (en) | 2007-09-13 | 2013-04-23 | Aerosat Corporation | Communication system with broadband antenna |
WO2009036322A1 (en) * | 2007-09-14 | 2009-03-19 | Xenoport, Inc. | Use of propofol prodrugs for treating neuropathic pain |
US20090075947A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched fospropofol |
KR20170125413A (ko) | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
US20090098209A1 (en) * | 2007-10-15 | 2009-04-16 | University Of Kansas | Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration |
WO2009120162A1 (ru) * | 2008-03-25 | 2009-10-01 | Zhukovskij Oleg Igorevich | Субстанция "ua' orion" |
EP2291084A4 (en) | 2008-05-20 | 2012-04-25 | Neurogesx Inc | CARBONATE PRODRUGS AND METHOD FOR THEIR USE |
BRPI0912326A2 (pt) * | 2008-05-20 | 2015-10-06 | Neurogesx Inc | análogos de acetaminofeno hidrossolúveis |
US20100069441A1 (en) | 2008-09-02 | 2010-03-18 | Mikhail Fedorovich Gordeev | Antimicrobial indoline compounds for treatment of bacterial infections |
WO2010048298A1 (en) | 2008-10-21 | 2010-04-29 | Proteolix, Inc. | Combination therapy with peptide epoxyketones |
CN101798302B (zh) | 2009-02-06 | 2014-11-05 | 上海盟科药业有限公司 | 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺 |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
CN101845057B (zh) * | 2009-03-27 | 2013-10-23 | 四川大学 | 取代苯酚的甲缩醛磷酸盐麻醉镇静药用化合物及制备方法 |
GB0905834D0 (en) | 2009-04-03 | 2009-05-20 | Seps Pharma Nv | Phosphonyl-containing phenolic derivatives useful as medicaments |
US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
DK2427467T3 (en) * | 2009-05-07 | 2015-11-09 | Univ Minnesota | Triptolid prodrugs |
CN101648973B (zh) * | 2009-09-03 | 2012-05-30 | 漆又毛 | 水溶性紫杉烷及制备方法 |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
CN102153607B (zh) * | 2010-02-11 | 2015-07-15 | 湖南方盛华美医药科技有限公司 | 水溶性喜树碱衍生物及包含其的药物组合物 |
US9359398B2 (en) | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
ES2829386T3 (es) | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
CN102946729B (zh) | 2010-04-07 | 2014-11-05 | 欧尼斯治疗公司 | 结晶肽环氧酮免疫蛋白酶体抑制剂 |
US8399535B2 (en) * | 2010-06-10 | 2013-03-19 | Zimmer, Inc. | Polymer [[s]] compositions including an antioxidant |
US20120065170A1 (en) | 2010-09-10 | 2012-03-15 | Micurx Pharmaceuticals, Inc. | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections |
PL2646035T3 (pl) * | 2010-12-02 | 2016-08-31 | Univ Kansas | Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne |
EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | AMINO-QUINOLINES AS KINASE INHIBITORS |
ITMI20110580A1 (it) * | 2011-04-08 | 2012-10-09 | Chemelectiva S R L | Iintermedi utili per la preparazione di fospropofol e processo per la loro preparazione |
UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
WO2013044064A1 (en) | 2011-09-22 | 2013-03-28 | Neurogesx, Inc. | Acetaminophen conjugates, compositions and methods of use thereof |
CN102516258B (zh) * | 2011-11-11 | 2014-06-25 | 正大天晴药业集团股份有限公司 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
CN102382133B (zh) * | 2011-12-02 | 2016-03-23 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠的制备及纯化方法 |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
US9580459B2 (en) * | 2013-04-26 | 2017-02-28 | Metselex, Inc. | Water-soluble ursodeoxycholic acid prodrugs |
US9708467B2 (en) | 2013-10-01 | 2017-07-18 | Zimmer, Inc. | Polymer compositions comprising one or more protected antioxidants |
US10981951B2 (en) * | 2014-01-31 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Therapeutics for the treatment of glaucoma |
ES2900838T3 (es) | 2014-02-21 | 2022-03-18 | Shanghai Micurx Pharmaceutical Co Ltd | Profármacos de O-carbonil fosforamidato solubles en agua para administración terapéutica |
WO2015138137A1 (en) | 2014-03-12 | 2015-09-17 | Zimmer, Inc. | Melt-stabilized ultra high molecular weight polyethylene and method of making the same |
EP3209302B1 (en) | 2014-10-21 | 2019-04-24 | AbbVie Inc. | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
US10265891B2 (en) | 2014-12-03 | 2019-04-23 | Zimmer, Inc. | Antioxidant-infused ultra high molecular weight polyethylene |
CN106674270A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠无水合物及晶型及其制备方法和用途 |
CN106674269A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠四水合物及晶型及其制备方法和用途 |
CN106674268A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠三水合物及晶型及其制备方法和用途 |
AU2016367708B2 (en) | 2015-12-09 | 2022-07-14 | Phosphagenics Limited | Pharmaceutical formulation |
WO2017147146A1 (en) * | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
EP3445346A1 (en) * | 2016-04-20 | 2019-02-27 | AbbVie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
US11331271B2 (en) * | 2016-05-27 | 2022-05-17 | The Johns Hopkins University | Buccal, sublingual and intranasal delivery of fospropofol |
WO2018017518A2 (en) | 2016-07-21 | 2018-01-25 | Astronics Aerosat Corporation | Multi-channel communications antenna |
MX2019006845A (es) | 2016-12-21 | 2019-10-15 | Avecho Biotechnology Ltd | Proceso. |
US10992052B2 (en) | 2017-08-28 | 2021-04-27 | Astronics Aerosat Corporation | Dielectric lens for antenna system |
US10174138B1 (en) * | 2018-01-25 | 2019-01-08 | University Of Massachusetts | Method for forming highly reactive olefin functional polymers |
CN109456360B (zh) * | 2018-12-17 | 2021-05-14 | 河南中医药大学 | 一种磷丙泊酚钠的制备方法 |
WO2020156189A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川科伦博泰生物医药股份有限公司 | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 |
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
CN113666958A (zh) * | 2020-05-13 | 2021-11-19 | 成都百裕制药股份有限公司 | 大麻素衍生物及其制备方法和在医药上的应用 |
TW202304524A (zh) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Cd70結合劑、其結合物及其使用方法 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2829151A (en) | 1952-11-03 | 1958-04-01 | Dow Chemical Co | Chlorotoloxy-ethyl phosphates |
US3271314A (en) | 1958-12-04 | 1966-09-06 | Ethyl Corp | 2, 6-diisopropylphenol |
GB1146173A (en) | 1966-06-18 | 1969-03-19 | Geigy Uk Ltd | Production of triaryl phosphates |
US3723578A (en) | 1970-10-13 | 1973-03-27 | Gaf Corp | Phosphate esters of ethers of thiol substituted phenols |
US4171272A (en) | 1977-12-02 | 1979-10-16 | Fmc Corporation | Turbine lubricant |
FR2601259B1 (fr) | 1986-07-11 | 1990-06-22 | Rhone Poulenc Chimie | Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives. |
US5053512A (en) | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US4894456A (en) | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5106742A (en) | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5364858A (en) | 1987-03-31 | 1994-11-15 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5122526A (en) | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
US5244903A (en) | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5180722A (en) | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
US5049668A (en) | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
US5122606A (en) | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
MY103951A (en) | 1988-01-12 | 1993-10-30 | Kao Corp | Detergent composition |
CA2014539C (en) | 1989-04-17 | 2000-07-25 | Shinichiro Umeda | Water borne metallic coating composition |
US5091211A (en) | 1989-08-17 | 1992-02-25 | Lord Corporation | Coating method utilizing phosphoric acid esters |
JPH03209414A (ja) | 1990-01-12 | 1991-09-12 | Nikon Corp | 焦点調節装置 |
AU660918B2 (en) | 1990-10-17 | 1995-07-13 | Arysta Lifescience Corporation | Method and composition for enhancing uptake and transport of bioactive agents in plants |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
CA2111527C (en) | 1992-12-24 | 2000-07-18 | Jerzy Golik | Phosphonooxymethyl ethers of taxane derivatives |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5731356A (en) * | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
US5646159A (en) | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
IT1270093B (it) | 1994-09-28 | 1997-04-28 | Zambon Spa | Processo per la purificazione di 2,6-diisopropilfenolo |
TW354293B (en) | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
US5804682A (en) | 1995-11-29 | 1998-09-08 | Henkel Corporation | Aqueous dispersions of polyamides |
US5637625A (en) | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
US5746973A (en) | 1996-07-10 | 1998-05-05 | Naraghi; Ali | Method for reducing odorant depletion |
CA2318817A1 (en) * | 1998-01-29 | 1999-08-05 | Bristol-Myers Squibb Company | Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
-
1998
- 1998-08-07 US US09/131,385 patent/US6204257B1/en not_active Expired - Lifetime
-
1999
- 1999-06-08 UA UA2001031520A patent/UA73479C2/ru unknown
- 1999-08-06 CZ CZ20010479A patent/CZ304020B6/cs not_active IP Right Cessation
- 1999-08-06 JP JP2000563666A patent/JP4554081B2/ja not_active Expired - Fee Related
- 1999-08-06 HU HU0200317A patent/HU229401B1/hu not_active IP Right Cessation
- 1999-08-06 PL PL347211A patent/PL198141B1/pl unknown
- 1999-08-06 AT AT99939030T patent/ATE319723T1/de active
- 1999-08-06 BR BR9912853-5A patent/BR9912853A/pt not_active Application Discontinuation
- 1999-08-06 CN CNA2005100524949A patent/CN1680402A/zh active Pending
- 1999-08-06 CN CNB998114405A patent/CN1198834C/zh not_active Expired - Fee Related
- 1999-08-06 WO PCT/US1999/017779 patent/WO2000008033A1/en active IP Right Grant
- 1999-08-06 DK DK99939030T patent/DK1102776T3/da active
- 1999-08-06 NZ NZ509795A patent/NZ509795A/en not_active IP Right Cessation
- 1999-08-06 EP EP99939030A patent/EP1102776B1/en not_active Expired - Lifetime
- 1999-08-06 AU AU53394/99A patent/AU769755B2/en not_active Ceased
- 1999-08-06 CA CA2339834A patent/CA2339834C/en not_active Expired - Fee Related
- 1999-08-06 ES ES99939030T patent/ES2268876T3/es not_active Expired - Lifetime
- 1999-08-06 PT PT99939030T patent/PT1102776E/pt unknown
- 1999-08-06 IL IL14131699A patent/IL141316A/en not_active IP Right Cessation
- 1999-08-06 EP EP06004146A patent/EP1683803A1/en not_active Withdrawn
- 1999-08-06 KR KR1020017001674A patent/KR100662799B1/ko not_active IP Right Cessation
- 1999-08-06 DE DE69930269T patent/DE69930269T2/de not_active Expired - Lifetime
- 1999-08-06 TR TR2001/00772T patent/TR200100772T2/xx unknown
- 1999-08-06 RU RU2001106614/04A patent/RU2235727C2/ru not_active IP Right Cessation
- 1999-08-06 MX MXPA01001431A patent/MXPA01001431A/es active IP Right Grant
-
2000
- 2000-12-08 US US09/733,817 patent/US6451776B2/en not_active Expired - Lifetime
-
2001
- 2001-02-07 ZA ZA200101039A patent/ZA200101039B/en unknown
- 2001-02-07 NO NO20010659A patent/NO330357B1/no not_active IP Right Cessation
-
2002
- 2002-07-29 US US10/208,647 patent/US6872838B2/en not_active Expired - Fee Related
-
2003
- 2003-01-02 HK HK03100006.9A patent/HK1047939B/zh not_active IP Right Cessation
-
2004
- 2004-11-17 US US10/991,348 patent/US7244718B2/en not_active Expired - Fee Related
-
2006
- 2006-06-02 CY CY20061100710T patent/CY1105043T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001106614A (ru) | Растворимые в воде пролекарства из затрудненных спиртов или фенолов | |
CA2339834A1 (en) | Water soluble prodrugs of hindered alcohols or phenols | |
JP2002522443A5 (ru) | ||
AU2003231765B9 (en) | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such | |
EP0637959B1 (en) | Soluble analogs of probucol | |
CA1149407A (en) | Polyether compounds, their production and their medicinal use | |
KR0125931B1 (ko) | 기관내 허혈병의 치료용 조성물 | |
US6239119B1 (en) | Topical administration of amifostine and related compounds | |
RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
KR960004345A (ko) | 2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 | |
EP2740736A1 (fr) | Derives aminophosphiniques utiles dans le traitement de la douleur | |
KR20010070962A (ko) | 유기 인 화합물 및 이의 용도 | |
EP2139463B1 (en) | Anti-infective agents | |
DE69315827T2 (de) | Neue acylierte phospholipid-arzneimittel | |
EP1038534A2 (en) | Process for the preparation of a conjugate of pharmacologically active substances | |
KR19990063988A (ko) | 락트산의 부티레이트 프로드럭 | |
WO2006121822B1 (en) | USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA | |
EP0579222B1 (en) | Lipid metabolism improving composition | |
US7495011B2 (en) | Anti-coronavirus drug | |
US20090203776A1 (en) | Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects | |
WO2000051615B1 (en) | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor | |
FR2481281A1 (fr) | Derives de la nonaprenylamine, leurs sels acides d'addition et composition pharmaceutique renfermant ces produits | |
CA2467773A1 (en) | Acyloxymethyl esters of c4-16 n-alkane-dicarboxylic acids for the treatment of acne and other related skin disorders | |
KR840002464B1 (ko) | 지방족 포스포노포름산 모노에스테르의 제조방법 | |
WO2023177995A2 (en) | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |